Syntopix Group plc
13 December 2006
For immediate release 13 December 2006
SYNTOPIX GROUP PLC
('Syntopix' or 'the Group')
BOARD CHANGES
Syntopix Group plc (AIM: SYN), the drug discovery and development group focused
on dermatological diseases, is pleased to announce that Stephen Philip Jones BSc
(Hons) Pharm, PhD, MRPharmS, (aged 49), has been appointed as Chief Executive
Officer (having been Chief Operating Officer since 1 July 2006). The appointment
is effective from 1 January 2007. At the same time Rod Adams (Chief Executive
Officer) has been appointed as Chairman of the Company and Gwyn Humphreys has
been appointed as the Company's senior non-executive Director.
There are no further disclosures to be made in accordance with Schedule 2 (g) of
the AIM rules.
Commenting on the Board changes, Rod Adams, said: 'I am delighted that Stephen
has taken the position of Chief Executive. Stephen has grown into this role
having spent six months working at Syntopix and I believe that his experience at
GSK in drug development and consumer healthcare will stand him in good stead to
take the business forward. I am pleased to be taking over as Chairman and look
forward to continuing to work alongside Stephen and the Syntopix management
team. We are all delighted that Gwyn is staying on the Syntopix Board as a
senior non-executive Director and I would like to thank him for his hard work
and support as Chairman. We have a solid management team in place to take the
Company and the exciting products within our portfolio through clinical
development.'
ENDS
For further information please contact:
Syntopix Group plc 0845 125 9204
Stephen Jones, Chief Executive officer
Rod Adams, Chairman
KBC Peel Hunt Ltd 020 7418 8900
Megan MacIntyre
Buchanan Communications 020 7466 5000
Mary-Jane Johnson
Notes to editors
About Syntopix Group plc
Syntopix, a group focused on the discovery and development of drugs for the
topical treatment of dermatological diseases, was founded in 2003 as a spin-out
from the University of Leeds by Dr Jon Cove and Dr Anne Eady, two of the leading
experts in skin microbiology, with initial funding from The Wellcome Trust.
Syntopix' strategy is to seek to reduce the risks and costs of drug discovery
and development by discovering novel uses for known compounds; by concentrating
on compounds and combinations of compounds that have a history of safe use; and
working with compounds that have known properties, for example antimicrobials
and anti-inflammatories. The Group currently has seven pending UK patent
applications.
Syntopix is currently concentrating on acne and Staphylococcus aureus infections
and has identified a pipeline of lead drug candidates that it intends to take
through pre-clinical and, as appropriate, clinical trials. The Group intends to
out-license products to commercial partners on obtaining proof of principle and
to seek co-development partnerships.
The Group is based at the Institute of Pharmaceutical Innovation in Bradford,
giving access to the expertise in skin biology, formulation and toxicology at
the universities of Bradford and Leeds.
Syntopix' shareholders include Techtran Group Limited (a subsidiary of IP Group
plc), The Wellcome Trust Limited, University of Leeds Limited, White Rose
Technology Limited and Ridings Early Growth Investment Company Limited.
Syntopix joined the AIM market of the London Stock Exchange in March 2006.
For further information please visit www.syntopix.com.
This information is provided by RNS
The company news service from the London Stock Exchange